New study identifies how obesity-related liver cancer becomes more aggressive and resistant to treatment

A research team affiliated with UNIST has made a significant discovery explaining why liver cancers associated with obesity and metabolic disorders tend to be more aggressive and less responsive to conventional treatments. The study reveals that a specific signaling pathway involving endotrophin—a protein secreted during liver fibrosis—and the receptor protein CD44 promotes tumor malignancy and drug resistance.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup